Special Issue "Therapeutic Approaches for Type 1 and Type 2 Diabetes"

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: closed (15 December 2019) | Viewed by 489

Special Issue Editors

Institute for Health and Sport, Victoria University, Melbourne, VIC 3011, Australia
Interests: cancer; autoimmunity; mental health; vaccines; exercise; infectious diseases; drugs; healthy aging; bioactives
Special Issues, Collections and Topics in MDPI journals
Dr. Vanessa Barriga
E-Mail Website
Guest Editor
Institute for Health and Sport, Victoria University, Melbourne, VIC, Australia
Interests: type-1 diabetes; immunology; immunotherapy; cancer; clinical trials; commercialisation

Special Issue Information

Dear Colleagues,

 Type 1 diabetes (T1D) is a life threatening disease which requires daily injections of insulin. At present, there is no cure for T1D. This disease develops when white blood cells that normally protect the body from infections get a signal to destroy cells in the insulin-producing  areas of the pancreas (beta cells); thus there is no insulin produced. The white blood cells, in particular T cells, are primarily responsible  for this destruction. Some of the  targets within the pancreas that the T cells recognise and attack are known and are used for therapeutics and vaccine purposes. B cells (auto-antibodies) have also been identified to damage the pancreas T1D patients.

 Type 2 diabetes (T2D) is a progressive condition where beta cells in the pancreas still make insulin but not enough or the the body's cells can't  respond properly to insulin that is made. This leads to high glucose levels. People with T2D are at risk of other co-morbid disorders including cardiovascular disease, mental health, inflammatory disorders and cancer.

This Special Issue invites researchers to submit reviews or original research papers on therapeutics against T1D and T2D.

Prof. Dr. Vasso Apostolopoulos
Dr. Vanessa Barriga
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop